MuSK CAART
Alternative Names: Muscle Specific Kinase chimeric autoantibody receptor T cells - Cabaletta Bio; MuSK Chimeric Autoantibody Receptor (CAAR) T Cells; MuSK-CAARTLatest Information Update: 09 Dec 2022
At a glance
- Originator University of Pennsylvania
- Developer Cabaletta Bio
- Class Gene therapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Myasthenia gravis